More than 2000 cancer immunotherapies in the pipeline: fight against cancer continues to heat up!
Very interesting article by Aiman Shalabi shared by Endpoints that there were 469 new PD-1/L1 cancer checkpoint studies launched this year. These studies require 52,000 patients to fully enroll for all these studies. Definitely a lot happening in the cancer therapy research and this is definitely good news.
The explosion of preclinical and clinical-stage programs that has erupted in immunotherapies is raising serious questions about the intrinsic value of each human study being mounted for more than 2,000 I/O agents now in development. Is there a more efficient way to manage studies, to get the maximum impact from every new trial? Can you justify all these trials, particularly small, single-site efforts?
Read the full article at: